Omnicell Inc

Omnicell Inc(OMCL)股票分析

$34.710

+0.201 (+0.58%)收盘时

Loading chart…
High
35.290
Open
34.510
VWAP
34.75
Vol
634.54K
Mkt Cap
1.21B
Low
34.260
Amount
22.05M
EV/EBITDA, TTM
9.32

Omnicell, Inc. is a healthcare technology provider focused on autonomous medication management, by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities. The Company is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. It provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. It provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions.

AI analysis of Omnicell Inc (OMCL)

sell

Omnicell Inc is not a good buy right now. The current price is $33.08, which is significantly lower than the analyst price targets ranging from $45 to $65, indicating potential upside. However, the RSI is at a very low 19.425, suggesting the stock is oversold, but the recent negative sentiment from insiders selling shares has increased by 151.38%. This raises concerns about the stock's short-term performance.

Analyst Ratings (8)

+56.15% upside
Buy
5 Buy
3 Hold
0 Sell
Current: 34.71
最低
46.00
平均
54.20
最高
63.00

Piper Sandler

2026-08-03

目标价

$45

Overweight

KeyBanc

2026-07-31

目标价

$65

Overweight

Wells Fargo

2026-07-31

目标价

$50

Overweight

Craig-Hallum

2026-04-29

目标价

$55

Buy

KeyBanc

2026-04-29

目标价

$70

Overweight

估值指标

The current forward P/E ratio for Omnicell Inc (OMCL) is 29.50, compared to its 5-year average forward P/E of 30.67.

Forward P/E

Fair
5Y Average P/E
30.67
Current P/E
29.50
高估
42.20
低估
19.14

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
18.19
Current EV/EBITDA
9.32
高估
25.77
低估
10.61

Forward P/S

Fair
5Y Average P/S
2.27
Current P/S
1.22
高估
3.64
低估
0.91

Alphio AI Price Scenarios for OMCL

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%OMCL

$32.55

情景价格

B

Base

Base · 50%OMCL

$27.79

情景价格

B

Bear

Bear · 25%OMCL

$24.88

情景价格

Whales holding OMCL

C

Cramer Rosenthal McGlynn LLC

+ HoldingOMCL

-1.53%

3M Return

OMCL FAQ — answered by Alphio AI

Omnicell, Inc. is a healthcare technology provider focused on autonomous medication management, by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities. The Company is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. It provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. It provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions. It operates in the Healthcare sector (ELECTRONIC COMPUTERS industry).

Omnicell Inc is not a good buy right now. The current price is $33.08, which is significantly lower than the analyst price targets ranging from $45 to $65, indicating potential upside. However, the RSI is at a very low 19.425, suggesting the stock is oversold, but the recent negative sentiment from insiders selling shares has increased by 151.38%. This raises concerns about the stock's short-term performance.

8 analysts cover OMCL: 5 rate it Buy, 3 Hold and 0 Sell. The average price target is 54.20.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始